MARKET

SGBCF

SGBCF

Shanghai Henlius
OTCPK
--
NaN%
Closed 09:30 05/23 EDT
OPEN
--
PREV CLOSE
--
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
--
52 WEEK LOW
--
MARKET CAP
--
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
1D
Dr. Reddy’s in licenses biosimilar for J&J’s multiple myeloma therapy
Seeking Alpha · 02/06 17:07
About SGBCF
Shanghai Henlius Biotech Inc is a China-based company mainly engaged in the research and development, production and sale of monoclonal antibody (mAb) drugs and the provision of related technical services (except for the development and application of human stem cells, genetic diagnosis and therapy technology), the transfer of its own technology and the provision of related technical consulting services. The Company's products include HANQUYOU (trastuzumab for injection), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection) and HANBEITAI (bevacizumab injection) and others. The Company mainly conducts its businesses in domestic and Asia-Pacific, North America, South America, and European markets.

Webull offers Shanghai Henlius Biotech Inc stock information, including OTCPK: SGBCF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGBCF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGBCF stock methods without spending real money on the virtual paper trading platform.